(May 10, 2026)
Sixty percent enriched uranium, when fabricated into targets and irradiated in a research reactor, produces molybdenum‑99, a radioisotope that decays into technetium‑99m.
This single isotope is used in tens of millions of medical procedures worldwide each year, including cardiac scans and cancer diagnostics that are essential to modern medicine.
Iran has officially declared this medical application, and the International Atomic Energy Agency (IAEA) verified the conversion of a portion of Iran’s 60 percent enriched uranium into targets for molybdenum‑99 production in March 2022.